Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Common Equity (2016 - 2025)

Marimed (MRMD) has disclosed Common Equity for 15 consecutive years, with $54.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 19.93% to $54.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $54.3 million, a 19.93% decrease, with the full-year FY2024 number at $58.5 million, down 16.26% from a year prior.
  • Common Equity was $54.3 million for Q3 2025 at Marimed, down from $56.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $80.9 million in Q2 2023 to a low of $14.7 million in Q1 2021.
  • A 5-year average of $54.6 million and a median of $57.3 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 41994.93% in 2021, then fell 19.93% in 2025.
  • Marimed's Common Equity stood at $36.3 million in 2021, then skyrocketed by 57.88% to $57.3 million in 2022, then grew by 21.99% to $69.9 million in 2023, then decreased by 16.26% to $58.5 million in 2024, then dropped by 7.22% to $54.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Common Equity are $54.3 million (Q3 2025), $56.9 million (Q2 2025), and $57.8 million (Q1 2025).